References
- Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642–653. doi: 10.1038/s41574-020-0399-8
- Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabet Res Clin Pract. 2015;109(2):378–388. doi: 10.1016/j.diabres.2015.05.025
- Tuch BE. Clinical use of GLP-1 agonists and DPP4 inhibitors. Pancreatology. 2016;16(1):8–9. doi: 10.1016/j.pan.2015.05.465
- Liu Y, Hu Y. Novel DPP-4 inhibitors against diabetes. Future Med Chem. 2014;6(7):793–808. doi: 10.4155/fmc.14.39
- Singh AK. Dipeptidyl peptidase-4 inhibitors: novel mechanism of actions. Indian J Endocrinol Metab. 2014;18(6):753–759. doi: 10.4103/2230-8210.141319
- Stonehouse AH, Darsow T, Maggs DG. Incretin‐based therapies. J Diabetes. 2012;4(1):55–67. doi: 10.1111/j.1753-0407.2011.00143.x
- Booth G, Lipscombe L, Butalia S. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes. 2016;40(6):484–486. doi: 10.1016/j.jcjd.2016.09.003
- Standards of medical care in diabetes-2016 abridged for primary care providers. Clin Diabetes. 2016;34(1):3–21. doi: 10.2337/diaclin.34.1.3
- NICE guideline on type 2 diabetes in adults: management 2022. [cited 2023 Feb 7] Available from: https://www.nice.org.uk/guidance/ng28/resources/visual-summary-full-version-choosing-medicines-for-firstline-and-further-treatment-pdf-10956472093
- Nagao M, Sasaki J, Sugihara H, et al. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. Sci Rep. 2023;13(1):134. doi: 10.1038/s41598-022-27301-9
- Kanazawa I, Tanaka KI, Notsu M, et al. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. Diabet Res Clin Pract. 2017;123:9–17. doi: 10.1016/j.diabres.2016.11.010
- Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684
- White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889
- FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. [cited 2023 Jun 10] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes
- FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. [cited 2023 Jun 10]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain#:~:text=FDA%20Drug%20Safety%20Communication%3A%20FDA,cause%20severe%20joint%20pain%20%7C%20FDA
- Raj N, Fernandes S, Charyulu NR, et al. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Ther Adv Drug Saf. 2019;10:2042098619865413. doi: 10.1177/2042098619865413
- Huang J, Jia Y, Sun S, et al. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol. 2020;21(1):68. doi: 10.1186/s40360-020-00447-w
- Ohyama K, Shindo J, Takahashi T, et al. Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA adverse event reporting system (FAERS). Sci Rep. 2022;12(1):13122. doi: 10.1038/s41598-022-17366-x
- Fadini GP, Sarangdhar M, Avogaro A. Pharmacovigilance evaluation of the association between DPP-4 inhibitors and heart failure: stimulated reporting and moderation by drug interactions. Diabetes Ther. 2018;9(2):851–861. doi: 10.1007/s13300-018-0408-2
- Carnovale C, Mazhar F, Arzenton E, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®. Expert Opin Drug Saf. 2019;18(11):1099–1108. doi: 10.1080/14740338.2019.1668373
- FDA adverse event reporting system (FAERS) Public Dashboard Available from: https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis
- OpenVigil 2.1-MedDRA-v24 (2004Q1-2023Q1). [cited Jun 2023]. Available from: https://openvigil.sourceforge.net/
- Medical Dictionary for regulatory activities MedDRA Version 26.0. [cited Jun 2023]. Available from: https://tools.meddra.org/wbb/
- Practical aspects of signal detection in pharmacovigilance; Report of CIOMS working group VIII. [cited 2022 Nov] Available from: https://cioms.ch/wp-content/uploads/2018/03/WG8-Signal-Detection.pdf
- Mitra A, Ray S. Evaluation of the safety and efficacy of teneligliptin at a higher dose in indian type 2 diabetes patients: a retrospective analysis. Cureus. 2020;12(1):e6812. doi: 10.7759/cureus.6812
- Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4):919–931. doi: 10.1185/030079906X162746
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. doi: 10.1001/jama.2018.18269
- Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in older participants in the trial evaluating cardiovascular outcomes with Sitagliptin (TECOS). Diabetes Care. 2017;40(4):494–501. doi: 10.2337/dc16-1135
- Fu AZ, Johnston SS, Ghannam A, et al. Association Between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. 2016;39(5):726–734. doi: 10.2337/dc15-0764
- Sano M. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. J Cardiol. 2019;73(1):28–32. doi: 10.1016/j.jjcc.2018.07.004
- Schernthaner G, Cahn A, Raz I. Is the Use of DPP-4 Inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care. 2016;39(Suppl 2):S210–8. doi: 10.2337/dcS15-3009
- Packer M. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovasc Diabetol. 2018;17(1):9. doi: 10.1186/s12933-017-0648-x
- Shao S, Xu Q, Yu X, et al. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020;209:107503. doi: 10.1016/j.pharmthera.2020.107503
- Crickx E, Marroun I, Veyrie C, et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int. 2014;34(2):291–292. doi: 10.1007/s00296-013-2710-7
- Yokota K, Igaki N. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Intern Med. 2012;51(15):2041–2044. doi: 10.2169/internalmedicine.51.7592
- Men P, He N, Song C, et al. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis. Diabetes metab. 2017;43(6):493–500. doi: 10.1016/j.diabet.2017.05.013
- Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. doi: 10.1016/S0140-6736(19)32131-2
- Pinto LC, Rados DV, Barkan SS, et al. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep. 2018;8(1):782. doi: 10.1038/s41598-017-19055-6
- Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diab Obes Metab. 2014;16(1):48–56. doi: 10.1111/dom.12176
- Saito A, Kitayama J, Horie H, et al. Dipeptidyl peptidase (dpp)-4 inhibitor impairs the outcomes of patients with type 2 diabetes mellitus after curative resection for colorectal cancer. Cancer Res Commun. 2021;1(2):106–114. doi: 10.1158/2767-9764.CRC-21-0042
- Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of Bullous Pemphigoid: a pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020. Am J Clin Dermatol. 2021;22(6):891–900. doi: 10.1007/s40257-021-00625-4
- Gorrell MD, Wang XM, Park J, et al. Structure and function in dipeptidyl peptidase IV and related proteins. Adv Exp Med Biol. 2006;575:45–54.
- Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54(10):2988–2994. doi: 10.2337/diabetes.54.10.2988
- Faillie JL, Babai S, Crépin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014;51(3):491–497. doi: 10.1007/s00592-013-0544-0